Agios Says CHMP Adopts Positive Opinion For PYRUKYND To Treat Pyruvate Kinase Deficiency In Adults
(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion on September 15, 2022, recommending the granting of a marketing authorization for PYRUKYND (mitapivat) for the treatment of pyruvate kinase (PK) deficiency in adult patients.
PK deficiency is a rare, debilitating, lifelong hemolytic anemia. PYRUKYND is a first-in-class, oral PK activator that was recently approved by the U.S. Food and Drug Administration (FDA).
If approved by the European Commission (EC), PYRUKYND will be the first approved disease-modifying therapy for European patients with PK deficiency.
PYRUKYND was previously granted orphan drug designation by the EMA.
The positive CHMP opinion was based on results from two pivotal studies, ACTIVATE and ACTIVATE-T, conducted in not regularly transfused and regularly transfused adults with PK deficiency, respectively.
DAX Retreats After Firm Start, Down Marginally
Swiss Franc Rises Against Majors
Sensex, Nifty Retreat On US Tariff Worries
Bank Of Korea Stands Pat On Rates, Lifts 2025 Growth Outlook
European Shares Mostly Higher As Nvidia Outlook Lifts Sentiment
Asian Shares Rise As Nvidia Beats Expectations
U.S. Dollar Falls Amid Fed Rate Cut Speculation
